Therapy Detail

Therapy Name Ipilimumab + Nivolumab
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ipilimumab Yervoy BMS-734016 CTLA4 Antibody 11 Immune Checkpoint Inhibitor 99 Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (FDA.gov).
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 50 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for the treatment of metastatic melanoma, squamous NSCLC, metastatic small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR or MSI-H colorectal cancer as a single agent or in combination with Yervoy (ipilimumab) (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown melanoma not applicable Ipilimumab + Nivolumab Phase II Actionable In a Phase II trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) resulted in improved overall response rate (ORR) and pathologic complete response rate (pCR) compared to Opdivo (nivolumab) monotherapy in patients with stage III or IV melanoma, with a ORR of 73% (8/11) and pCR of 45% (5/11), however, demonstrated higher toxicity (PMID: 30297909; NCT02519322). 30297909
Unknown unknown melanoma not applicable Ipilimumab + Nivolumab FDA approved Actionable In a Phase III trial (CheckMate 067) that supported FDA approval, combination of Opdivo (nivolumab) and Yervoy (ipilimumab) and Opdivo (nivolumab) alone demonstrated improved efficacy compared to Yervoy (ipilimumab) in patients with untreated advanced melanoma, resulted in a median overall survival unreached in the combination arm, 36.9 and 19.9 months in nivolumab and ipilimumab monotherapy arms, and a median progression-free survival of 11.5, 6.9, and 2.9 months respectively (PMID: 30361170; NCT01844505). 30361170
Unknown unknown lung small cell carcinoma not applicable Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment is included in guidelines for small cell lung cancer patients who have relapsed after primary therapy (NCCN.org). detail...
Unknown unknown stomach cancer not applicable Ipilimumab + Nivolumab Phase Ib/II Actionable In a Phase I/II trial, Opdivo (nivolumab), alone or incombination with Yervoy (ipilimumab), demonstrated safety and efficacy in patients with chemotherapy-refractory gastric cancer, resulted in a disease control rate of 38% (61/160) (J Clin Oncol 34, 2016 (suppl; abstr 4010)). detail...
Unknown unknown renal cell carcinoma not applicable Ipilimumab + Nivolumab Phase I Actionable In a Phase I trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated safety using 2 different dosing regimens (N3I1=nivolumab 3mg/kg+ipilumumab 1mg/kg; N1I3=nivolumab 1mg/kg+ipilumumab 3mg/kg) in patients with metastatic renal cell carcinoma, and resulted in an objective response rate of 40.4% (19/47) in both N3I1 and N1I3 arms and a 2-year overall survival of 67% in the N3I1 arm and 70% in the N1I3 arm (PMID: 28678668; NCT01472081). 28678668
Unknown unknown renal cell carcinoma not applicable Ipilimumab + Nivolumab FDA approved Actionable In a Phase III trial (CheckMate 214) that supported FDA approval, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) resulted in improved median overall survival (not reached vs. 26.0 months), objective response rate (42%, 40 complete responses (CR), vs. 27%, 5 CR), and progression-free survival (11.6 vs 8.4 months) compared to Sutent (sunitinib) in patients with intermediate or poor risk renal cell carcinoma (PMID: 29562145; NCT02231749). 29562145
MET exon 14 non-small cell lung carcinoma unknown Ipilimumab + Nivolumab Clinical Study Actionable In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371). 30165371
Clinical Trial Phase Therapies Title Recruitment Status
NCT03335540 Phase I BMS-986205 + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Recruiting
NCT03463408 Phase I Ipilimumab + Nivolumab Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma Recruiting
NCT03043599 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Active, not recruiting
NCT03117309 Phase II Ipilimumab + Nivolumab Nivolumab Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma Recruiting
NCT03377023 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Recruiting
NCT02599402 Phase III Ipilimumab + Nivolumab Nivolumab Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Active, not recruiting
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Recruiting
NCT03430791 Phase II Ipilimumab + Nivolumab Nivolumab Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma Recruiting
NCT02996110 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) Recruiting
NCT03693846 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Recruiting
NCT03149159 Phase II Ipilimumab + Nivolumab Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab Withdrawn
NCT03668119 Phase II Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Recruiting
NCT03101566 Phase II Cisplatin + Gemcitabine + Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Recruiting
NCT02970981 Phase II Ipilimumab + Nivolumab Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma Active, not recruiting
NCT03918252 Phase II Ipilimumab + Nivolumab Nivolumab Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Not yet recruiting
NCT02892734 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Terminated
NCT03222076 Phase II Ipilimumab + Nivolumab Nivolumab Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Recruiting
NCT03604978 Phase Ib/II Ipilimumab + Nivolumab Nivolumab Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma Recruiting
NCT03162731 Phase I Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer Recruiting
NCT02741570 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02939300 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma Recruiting
NCT03274258 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma Recruiting
NCT02935634 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC) Recruiting
NCT02186249 Phase III Ipilimumab + Nivolumab Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) No longer available
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Recruiting
NCT03241186 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Recruiting
NCT03670056 Phase II Ipilimumab + Nivolumab A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy Not yet recruiting
NCT03597282 Phase I Ipilimumab + Nivolumab APX005M + Nivolumab Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC APX005M + NEO-PV-01 + Nivolumab + Poly ICLC Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma Recruiting
NCT03355976 Phase II Ipilimumab + Nivolumab Nivolumab BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting
NCT03956680 Phase I Ipilimumab + Nivolumab BMS-986301 An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers Recruiting
NCT03029780 Phase II Ipilimumab + Nivolumab An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma Active, not recruiting
NCT02978443 Phase II Ipilimumab + Nivolumab A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Recruiting
NCT03158129 Phase II Nivolumab Ipilimumab + Nivolumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Recruiting
NCT02872116 Phase III Capecitabine + Oxaliplatin Ipilimumab + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) Active, not recruiting
NCT03604991 Phase II Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting
NCT02320058 Phase II Ipilimumab + Nivolumab A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) Active, not recruiting
NCT02869789 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Recruiting
NCT03461952 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) Recruiting
NCT03776487 Phase Ib/II Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Recruiting
NCT03789110 Phase II Ipilimumab + Nivolumab NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Recruiting
NCT03651271 Phase II Ipilimumab + Nivolumab Nivolumab Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer Recruiting
NCT02982954 Phase III Ipilimumab + Nivolumab A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) Active, not recruiting
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy iImmunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Recruiting
NCT03377361 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread Recruiting
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA) Recruiting
NCT03048136 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) Withdrawn
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting
NCT03262779 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. Recruiting
NCT03068455 Phase III Nivolumab Ipilimumab Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) Active, not recruiting
NCT03707457 Phase I Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Recruiting
NCT03799445 Phase II Ipilimumab + Nivolumab Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma Not yet recruiting
NCT03391869 Phase III Ipilimumab + Nivolumab Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR) Recruiting
NCT02210117 Phase II Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) Active, not recruiting
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001) Recruiting
NCT03146650 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Recruiting
NCT02919683 Phase II Nivolumab Ipilimumab + Nivolumab Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Recruiting
NCT03425292 Phase I Temozolomide Ipilimumab + Nivolumab Nivolumab A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Recruiting
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting
NCT02714218 Phase III Ipilimumab + Nivolumab A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma Active, not recruiting
NCT03285321 Phase II Ipilimumab + Nivolumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03246958 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab in Thyroid Cancer Recruiting
NCT03104439 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Recruiting
NCT02823574 Phase II Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT03001882 Phase II Ipilimumab + Nivolumab An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03719131 Phase II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Rituximab Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Recruiting
NCT03520491 Phase II Ipilimumab + Nivolumab Nivolumab A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy Recruiting
NCT02864251 Phase III Nivolumab Ipilimumab + Nivolumab Carboplatin + Cisplatin + Pemetrexed A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722) Recruiting
NCT03256136 Phase II Carboplatin + Nivolumab + Pemetrexed Ipilimumab + Nivolumab A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer Recruiting
NCT03793166 Phase III Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Recruiting
NCT03873402 Phase III Nivolumab Ipilimumab + Nivolumab An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Recruiting
NCT02899299 Phase III Carboplatin + Cisplatin + Pemetrexed Ipilimumab + Nivolumab Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) Active, not recruiting
NCT03903640 Phase II Ipilimumab + Nivolumab Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis Not yet recruiting
NCT03220009 Phase II Ipilimumab + Nivolumab Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Active, not recruiting
NCT03600155 Phase I Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia Recruiting
NCT03749460 Phase Ib/II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Recruiting
NCT03033576 Phase II Ipilimumab Ipilimumab + Nivolumab Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery Recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT03065179 Phase II Ipilimumab + Nivolumab Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients Recruiting
NCT03937219 Phase III Cabozantinib + Nivolumab Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) Not yet recruiting
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting
NCT02985957 Phase II Ipilimumab + Nivolumab A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT02601014 Phase II Ipilimumab + Nivolumab Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Recruiting
NCT03126461 Phase II Ipilimumab + Nivolumab SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients Withdrawn
NCT03546686 Phase II Ipilimumab + Nivolumab Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer Recruiting
NCT02998528 Phase III Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed + Vinorelbine A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) Recruiting
NCT03425331 Phase II Ipilimumab + Nivolumab Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Recruiting
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT03646617 Phase II Ipilimumab + Nivolumab Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma Recruiting
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated
NCT03036098 Phase III Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer Recruiting
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Ipilimumab + Nivolumab Crizotinib Palbociclib Sunitinib Olaparib Cetuximab TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT03798639 Phase I Ipilimumab + Nivolumab Nivolumab Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer Recruiting
NCT03203473 Phase II Nivolumab Ipilimumab + Nivolumab Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Recruiting
NCT03172624 Phase II Ipilimumab + Nivolumab Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting
NCT02736123 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Withdrawn
NCT02785952 Phase III Nivolumab Ipilimumab + Nivolumab Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting
NCT03223155 Phase I Ipilimumab + Nivolumab Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer Recruiting
NCT03521830 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Recruiting
NCT03071406 Phase II Ipilimumab + Nivolumab Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Recruiting
NCT02231749 Phase III Ipilimumab + Nivolumab Sunitinib Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Active, not recruiting
NCT03138512 Phase III Ipilimumab + Nivolumab A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) Recruiting
NCT02880020 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02659059 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) Active, not recruiting
NCT02656706 Phase II Ipilimumab + Nivolumab BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial Recruiting
NCT03724968 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression Recruiting
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting
NCT02833233 Phase I Ipilimumab + Nivolumab A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer Active, not recruiting
NCT03203304 Phase I Nivolumab Ipilimumab + Nivolumab Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma Recruiting
NCT03367715 Phase II Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Recruiting
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Recruiting
NCT03143153 Phase III Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) Recruiting
NCT03528408 Phase II Ipilimumab + Nivolumab Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02659540 Phase I Ipilimumab + Nivolumab A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma Active, not recruiting
NCT03829111 Phase I Ipilimumab + Nivolumab CBM588 + Ipilimumab + Nivolumab CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer Recruiting
NCT02408861 Phase I Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors Recruiting
NCT03307616 Phase II Ipilimumab + Nivolumab Nivolumab Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting
NCT03575793 Phase Ib/II Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Recruiting
NCT03305445 Phase Ib/II Ipilimumab + Nivolumab Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Recruiting